Dear Health Care Professional Letter about comparative data on the lesser effectiveness regimen based on the medicinal product Tyverb (lapatinib) as compared on Herceptin (trastuzumab) based regimen
01.02.2013
The company GlaxoSmithKline d.o.o., the marketing authorisation holder for the medicinal product Tyverb 250 mg film-coated tablets (lapatinib), has, in collaboration with the Agency for Medicinal Product and Medical Devices (HALMED) sent out a letter to health care professionals about the comparative data based on the medicinal product Tyverb 250 mg film-coated tablets as compared to the regimen based on the medicinal product Herceptin 250 mg powder for solution for injection (trastuzumab) in certain patient groups.
Here you may view the Dear Health Care Professional letter (in Croatian).
We remind healthcare professionals that they should report any adverse reaction to HALMED, as well as quality defect. Patients who have developed any adverse reaction to medicinal product may report it directly to HALMED via form or on-line application, with recommendation regarding any adverse reaction they discover to consult with their doctor or pharmacist about the continuation of their therapy.
